Abstract
Bayer Pharma has licensed exclusive rights to develop and commercialise Trius Therapeutics’ torezolid phosphate (TR-701) for acute bacterial skin and skin structure infections (aBSSSI) and pneumonia in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding North and South Korea. Trius retains full rights to the drug in the US, Canada and the EU.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
